- Home
- ARMP vs NMT Comparison
ARMP vs NMT Comparison
Compare ARMP & NMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMP
- NMT
- Stock Information
- Founded
- ARMP N/A
- NMT 1993
- Country
- ARMP United States
- NMT United States
- Employees
- ARMP N/A
- NMT N/A
- Industry
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- NMT Finance/Investors Services
- Sector
- ARMP Health Care
- NMT Finance
- Exchange
- ARMP Nasdaq
- NMT Nasdaq
- Market Cap
- ARMP 92.4M
- NMT 107.6M
- IPO Year
- ARMP N/A
- NMT N/A
- Fundamental
- Price
- ARMP $2.94
- NMT $11.62
- Analyst Decision
- ARMP Strong Buy
- NMT
- Analyst Count
- ARMP 1
- NMT 0
- Target Price
- ARMP $9.00
- NMT N/A
- AVG Volume (30 Days)
- ARMP 12.5K
- NMT 19.1K
- Earning Date
- ARMP 11-12-2025
- NMT 01-01-0001
- Dividend Yield
- ARMP N/A
- NMT 3.21%
- EPS Growth
- ARMP N/A
- NMT N/A
- EPS
- ARMP N/A
- NMT N/A
- Revenue
- ARMP $6,868,000.00
- NMT N/A
- Revenue This Year
- ARMP $8.43
- NMT N/A
- Revenue Next Year
- ARMP N/A
- NMT N/A
- P/E Ratio
- ARMP N/A
- NMT N/A
- Revenue Growth
- ARMP 84.67
- NMT N/A
- 52 Week Low
- ARMP $0.90
- NMT $9.05
- 52 Week High
- ARMP $3.14
- NMT $10.93
- Technical
- Relative Strength Index (RSI)
- ARMP 61.74
- NMT 63.62
- Support Level
- ARMP $2.79
- NMT $11.14
- Resistance Level
- ARMP $3.03
- NMT $11.58
- Average True Range (ATR)
- ARMP 0.15
- NMT 0.11
- MACD
- ARMP 0.02
- NMT 0.04
- Stochastic Oscillator
- ARMP 72.97
- NMT 89.96
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
About NMT Nuveen Massachusetts Quality Municipal Income Fund
Nuveen Massachusetts Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's objective seeks to provide current income exempt from both regular federal and Massachusetts income taxes and to enhance portfolio value relative to the Massachusetts municipal bond market by investing in tax-exempt Massachusetts municipal obligations that are underrated or undervalued or that represent municipal market sectors that are undervalued.